MRC1 and neoplasm: Despite significantly improved treatment options due to the availability of ICIs, therapy resistance is still a major problem for the treatment of CRCs (reviewed by [24]); although MMR deficiency in CRCs has been established as a striking biomarker for response to ICIs, MMR-deficient CRCs frequently present primary resistance to ICIs and early tumor progression [25,26,27,28].